IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback